(Q40554084)

21 September 2017

title

Potential Role of Neuroprotective Agents in the Treatment of Patients with Acute Ischemic Stroke (English)

1 reference

21 September 2017

Potential role of neuroprotective agents in the treatment of patients with acute ischemic stroke (English)

1 reference

https://api.crossref.org/works/10.1007/S11936-003-0033-9

Cardiology and cardiovascular medicine

24 March 2024

main subject

1 reference

https://api.crossref.org/works/10.1007/S11936-003-0033-9

24 March 2024

1

Bruce Ovbiagele

1 reference

21 September 2017

3

Sidney Starkman

1 reference

21 September 2017

2

Chelsea S. Kidwell

1 reference

21 September 2017

4

Jeffrey L. Saver

1 reference

21 September 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14575621

24 March 2024

publication date

1 December 2003

1 reference

full work available at URL

21 September 2017

http://link.springer.com/content/pdf/10.1007/s11936-003-0033-9.pdf

file format

Portable Document Format

1 reference

https://api.crossref.org/works/10.1007/S11936-003-0033-9

http://link.springer.com/article/10.1007/s11936-003-0033-9/fulltext.html

24 March 2024

1 reference

https://api.crossref.org/works/10.1007/S11936-003-0033-9

http://link.springer.com/content/pdf/10.1007/s11936-003-0033-9

24 March 2024

1 reference

https://api.crossref.org/works/10.1007/S11936-003-0033-9

Current treatment options in cardiovascular medicine

24 March 2024

published in

1 reference

21 September 2017

volume

5

1 reference

21 September 2017

issue

6

1 reference

21 September 2017

page(s)

441-449

1 reference

https://scigraph.springernature.com/pub.10.1007/s11936-003-0033-9

21 September 2017

exact match

0 references

cites work

Trends in acute ischemic stroke trials through the 20th century

1 reference

https://api.crossref.org/works/10.1007%2FS11936-003-0033-9

Recommendations for clinical trial evaluation of acute stroke therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-003-0033-9

Moderate hypothermia in the treatment of patients with severe middle cerebral artery infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-003-0033-9

Human albumin therapy of acute ischemic stroke: marked neuroprotective efficacy at moderate doses and with a broad therapeutic window.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-003-0033-9

The Clomethiazole Acute Stroke Study in tissue-type plasminogen activator-treated stroke (CLASS-T): final results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-003-0033-9

Admission body temperature predicts long-term mortality after acute stroke: the Copenhagen Stroke Study

21 January 2018

1 reference

12 December 2020

Neuroprotective effect of delayed moderate hypothermia after focal cerebral ischemia: an MRI study

1 reference

12 December 2020

Why do neuroprotective drugs work in animals but not humans?

1 reference

12 December 2020

Tissue plasminogen activator for acute ischemic stroke

1 reference

12 December 2020

Why do all drugs work in animals but none in stroke patients? 2. Neuroprotective therapy

1 reference

12 December 2020

Endovascular cooling for moderate hypothermia in patients with acute stroke: first results of a novel approach

1 reference

12 December 2020

Design of the Intravenous Magnesium Efficacy in Acute Stroke (IMAGES) trial

1 reference

12 December 2020

Neuroprotection in acute ischaemic stroke. Current status and future potential

1 reference

12 December 2020

Neuroprotection and the ischemic cascade

1 reference

12 December 2020

Feasibility and safety of inducing modest hypothermia in awake patients with acute stroke through surface cooling: A case-control study: the Copenhagen Stroke Study

1 reference

12 December 2020

Adventures in the pathophysiology of brain ischemia: penumbra, gene expression, neuroprotection: the 2002 Thomas Willis Lecture

1 reference

12 December 2020

Combination Therapy Stroke Trial: recombinant tissue-type plasminogen activator with/without lubeluzole

1 reference

12 December 2020

Neuroprotective agents for the treatment of acute ischemic stroke

1 reference

12 December 2020

Treatment of comatose survivors of out-of-hospital cardiac arrest with induced hypothermia

1 reference

12 December 2020

What evidence supports use of erythropoietin as a novel neurotherapeutic?

1 reference

12 December 2020

Albumin therapy of transient focal cerebral ischemia: in vivo analysis of dynamic microvascular responses

1 reference

12 December 2020

Acetaminophen for altering body temperature in acute stroke: a randomized clinical trial

1 reference

12 December 2020

Magnesium for neuroprotection in ischaemic stroke: rationale for use and evidence of effectiveness

1 reference

12 December 2020

New perspectives on developing acute stroke therapy

1 reference

12 December 2020

Recommendations for standards regarding preclinical neuroprotective and restorative drug development

1 reference

12 December 2020

Early major ischemic changes on computed tomography should not preclude use of tissue plasminogen activator.

series ordinal

19

1 reference

https://api.crossref.org/works/10.1007/S11936-003-0033-9

24 March 2024

Identifiers

1 reference

Dimensions Publication ID

21 September 2017

1044386595

0 references

1 reference